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ABSTRACT 
Treatment switching often has a crucial impact on estimates of effectiveness and cost-effectiveness of new 
oncology treatments. Rank preserving structural failure time models (RPSFTM) and two-stage estimation (TSE) 
methods estimate ‘counterfactual’ (i.e. had there been no switching) survival times and incorporate re-censoring 
to guard against informative censoring in the counterfactual dataset. However, re-censoring causes a loss of 
longer term survival information which is problematic when estimates of long-term survival effects are required, 
as is often the case for health technology assessment decision making. We present a simulation study designed 
to investigate applications of the RPSFTM and TSE with and without re-censoring, to determine whether re-
censoring should always be recommended within adjustment analyses. We investigate a context where 
switching is from the control group onto the experimental treatment in scenarios with varying switch 
proportions, treatment effect sizes and time-dependencies, disease severity and switcher prognosis. Methods 
were assessed according to their estimation of control group restricted mean survival (that would be observed in 
the absence of switching) at the end of the simulated trial follow-up. We found that RPSFTM and TSE analyses 
which incorporated re-censoring usually produced negative bias (i.e. under-estimating control group restricted 
mean survival and therefore over-estimating the treatment effect). RPSFTM and TSE analyses that did not 
incorporate re-censoring consistently produced positive bias (i.e. under-estimating the treatment effect) which 
was often smaller in magnitude than the bias associated with the re-censored analyses. We believe that analyses 
should be conducted with and without re-censoring, as this may provide decision makers with useful 
information on where the true treatment effect is likely to lie. Analyses that incorporate re-censoring should not 
always represent the default approach when the objective is to estimate long-term survival times and treatment 
effects on long-term survival. 
 
Key words: Treatment switching; treatment crossover; survival analysis; overall survival; oncology; health 
technology assessment; time-to-event outcomes; prediction; re-censoring 
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INTRODUCTION 
Treatment switching commonly occurs in randomised controlled trials (RCTs), whereby patients randomised to 
the control group are permitted to switch onto the experimental treatment during trial follow-up. Switching is 
permitted primarily due to ethical considerations, and the rationale for switching, its implications and analytical 
methods for adjusting for it has been the focus of much discussion in the literature.[1-4] Given that switching in 
trials is likely to continue to occur and often has a large impact on estimates of the effectiveness of new 
treatments, it is important for regulators and health technology assessors to engage with methods that attempt to 
adjust for switching. Several statistical adjustment methods are available, but all make strong assumptions that 
are not possible to test perfectly. In addition, each of these methods can be applied in a multitude of ways and 
seemingly innocuous choices around how a particular method is applied can importantly affect the results they 
produce. This is sure to influence the thinking of decision makers when they seek to interpret the results of 
adjustment analyses, and may lead to a lack of trust in adjustment methods. It has been suggested that decision 
makers require manufacturers to describe and justify adjustment analyses in detail – including rationale for each 
application decision made – in order that robust and informed decisions can be made.[5,6] 
Whether or not to apply re-censoring represents an application decision that can have a substantial impact on the 
results of Rank Preserving Structural Failure Time Model (RPSFTM) and two-stage adjustment analyses. In a 
recently published study, Latimer et al. presented a series of adjustment analyses applied to a trial analysing the 
effect of trametinib compared to chemotherapy in patients with metastatic melanoma.[7] A standard intention-
to-treat (ITT) analysis resulted in a hazard ratio (HR) of 0.72 (95% confidence interval (CI) 0.52 to 0.98). 
However, 67% of control group patients had switched onto the experimental treatment. An RPSFTM analysis 
designed to adjust for the treatment switching gave a HR of 0.38 (95% CI 0.15 to 0.95) when re-censoring was 
applied, and an HR of 0.49 (95% CI 0.25 to 0.96) when re-censoring was not applied. The HRs for a two-stage 
analysis to adjust for the treatment switching were 0.43 (95% CI 0.20 to 0.96) with re-censoring and 0.53 (95% 
CI 0.29 to 0.97) without re-censoring. Such substantial differences in the point-estimate of the treatment effect 
can be critical particularly for estimates of the expected cost-effectiveness of new interventions – overall 
survival benefit estimates are often the most influential parameters within cost-effectiveness models of cancer 
interventions.[8] Cost-effectiveness analyses are key factors in reimbursement decisions made on new 
healthcare interventions around the world.[9-12] 
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It is generally recommended to apply re-censoring – which will be described in the next section – when 
applying RPSFTM and two-stage adjustment methods.[13-15] However, it is recognised that whilst re-censoring 
helps avoid one type of bias – informative censoring – it can result in a type of missing information bias when 
the treatment effect changes over time, because longer-term information is lost.[1,15-18] It may therefore be 
possible that in some situations analyses which do not re-censor are preferable to analyses which do. Currently, 
little is known about the impact of re-censoring in realistic scenarios, or how results should be interpreted when 
the choice of whether or not to apply re-censoring has a large impact on the estimated treatment effect. 
Simulation studies have shown that adjustment methods produce varying levels of bias depending upon factors 
such as the switch proportion and the treatment effect size, but have only considered applications of adjustment 
methods that include re-censoring.[19-21] In this paper we conduct a new simulation study to investigate the 
performance of adjustment methods with and without applying re-censoring. Our objective is to determine 
whether it is possible to discern the likely impact of re-censoring in various scenarios, in order that expectations 
over the likely bias associated with analyses that do or do not apply re-censoring can be informed. This should 
allow analysts and decision-makers to better interpret the results of adjustment analyses, enabling more 
constructive use of adjustment methods.     
METHODS   
Statistical adjustment methods 
The RPSFTM [22] and two-stage adjustment methods [20] can be used to estimate counterfactual survival times 
in the presence of treatment switching in RCTs – that is, they estimate survival times that would have been 
observed if treatment switching had not occurred.  
The simple one-parameter version of the RPSFTM splits the observed event time, 𝑇𝑖 , for each patient into time 
spent on the control treatment, 𝑇𝐴𝑖 , and time spent on the intervention treatment, 𝑇𝐵𝑖 . For patients who are 
randomised to the intervention treatment, and who do not switch onto the control treatment (that is, when there 
is full compliance in the treatment group), 𝑇𝐴𝑖  is equal to zero. For patients randomised to the control group who 
do not switch onto the intervention (i.e. compliance is full in the control group) 𝑇𝐵𝑖  is equal to zero. However, 
for patients who switch treatments (for whom compliance is therefore only partial) both 𝑇𝐴𝑖  and 𝑇𝐵𝑖  will be 
greater than zero. The RPSFTM method relates 𝑇𝑖  to the counterfactual survival time (𝑈𝑖) with the following 
causal model: 
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𝑈𝑖 = 𝑇𝐴𝑖 + 𝑒
𝜓0𝑇𝐵𝑖      (1) 
𝑒−𝜓0  represents the acceleration factor (AF) associated with the intervention – the amount by which an 
individual’s expected survival time is increased by treatment. The RPSFTM assumes that there is a common 
treatment effect associated with the experimental treatment (i.e. that the treatment effect, 𝑒𝜓0 , is the same no 
matter when the treatment is received) and that if no patients received the experimental treatment average 
survival times in the randomised groups would be equal. Given these assumptions, g-estimation is used to 
estimate 𝜓0, with the true value being that for which counterfactual survival times (𝑈𝑖) are independent of 
randomised group.[22] This is done by computing 𝑈𝑖 for a range of values of 𝜓 and each time testing whether 
the 𝑈𝑖 are independent of randomised group. 
The two-stage adjustment method also involves estimating counterfactual survival times. The counterfactual 
survival model (1) is again used, but the two-stage adjustment method estimates 𝜓 based upon an assumption of 
no unmeasured confounding. Under the simple two-stage adjustment method, it is assumed that treatment 
switching only occurs after a disease-related secondary baseline, such as disease progression. Then (assuming 
switching is only from the control group onto the experimental treatment), post-secondary baseline survival 
times in control group patients who switch onto the experimental treatment are compared to those in control 
group patients who do not switch, using a parametric accelerated failure time model (e.g. Weibull or 
Generalised Gamma), controlling for prognostic covariates measured at the secondary baseline time-point and 
including the switch indicator as a time-dependent variable which equals ‘1’ after the time of switch. A 
treatment effect (𝜓) associated with switching is then obtained, and is incorporated into (1) to estimate 
counterfactual survival times in switching patients. 
Censoring is problematic for the RPSFTM and two-stage method due to an association between treatment 
received, counterfactual censoring time, and prognosis. For ease of exposition, we assume the experimental 
treatment is beneficial, though similar arguments apply if it is harmful. The counterfactual survival model then 
involves shrinking survival times for all patients who receive the experimental treatment. For some patients, the 
event time (usually death) may not be observed – instead it is censored. For these patients, the RPSFTM and 
two-stage methods estimate shrunken censoring times. The amount by which survival or censoring times are 
shrunk depends upon the size of the treatment effect and the duration for which the experimental treatment is 
8 
 
received. Counterfactual censoring times will be prone to informative censoring bias if either/both of the two 
following criteria are met: 
 If treatment discontinuation/initiation decisions are related to prognostic factors;  
 If the duration of treatment is related to prognostic factors.   
It has been suggested that possible bias associated with informative censoring can be avoided by breaking the 
dependence between the counterfactual censoring time and treatment received by re-censoring the 
counterfactual survival time associated with a given value of 𝜓 (that is, 𝑈𝑖(𝜓)) for all patients at the minimum 
of the administrative censoring time 𝐶𝑖  and 𝐶𝑖 exp 𝜓, representing the earliest possible censoring time over all 
possible treatment trajectories, 𝐷𝑖
∗(𝜓). 𝑈𝑖(𝜓) is then replaced by 𝐷𝑖
∗(𝜓) if 𝐷𝑖
∗(𝜓) <  𝑈𝑖(𝜓).[13-15]  
Unfortunately, re-censoring involves a loss of information as the survival data are artificially censored at a time-
point earlier than the follow-up times observed in the trial. A treatment effect calculated by comparing 
counterfactual control group survival times and observed experimental group survival times is therefore based 
upon shorter-term data for the control group (see Figure 1, which presents counterfactual survival curves with 
and without re-censoring from the trametinib example mentioned previously). If the treatment effect is not 
constant over time, using the re-censored survival data would result in bias if the objective is to estimate the 
overall longer-term treatment effect.[15] It is common for regulatory and health technology assessment (HTA) 
agencies to attempt to estimate longer-term treatment effects for interventions that affect survival, with HTA 
agencies typically requiring estimates of lifetime treatment effects.[9-12] There has recently been considerable 
interest in moving away from the hazard ratio as a summary of the treatment effect, partly because treatment 
effects are often observed to change over time.[23,24] Therefore, there is a legitimate question as to whether re-
censoring or not re-censoring is likely to produce least bias in an adjustment analysis, given an objective of 
estimating long-term survival times and treatment effects. 
We aim to investigate whether re-censoring or not re-censoring is likely to produce least bias in a range of 
realistic scenarios.  
Simulation study design 
We simulated independent datasets in which treatment switching was permitted, and in which the true survival 
times for each treatment option were known. We then applied each of the switching adjustment methods with 
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and without re-censoring, and compared the bias in their estimation of restricted mean survival time (RMST) in 
the control group. We focussed on control group RMST because we simulated scenarios where switching was 
only in the control group and therefore the objective of the adjustment analysis was to estimate counterfactual 
survival times for the control group. For each method we also calculated the empirical standard error, root mean 
squared error and coverage associated with estimates of control group RMST. The study was designed such that 
the data simulated reflected data typically observed in clinical trials in the advanced/metastatic cancer disease 
area. The simulation study was conducted using Stata software, version 13.1.[25]   
Underlying survival times 
A joint survival and longitudinal model was used to simultaneously generate a continuous time-dependent 
covariate (referred to as ‘biomarker’) and survival times,[26] similar to the approach taken in a previous 
simulation study.[19] The underlying biomarker level influenced survival and was influenced by treatment 
received, and observed values of the biomarker (which were subject to an error term) influenced the probability 
of treatment switching. Within the data-generating joint model, the longitudinal model for the underlying 
biomarker value for the ith patient at time t was:   
𝑏𝑖𝑜𝑚𝑎𝑟𝑘𝑒𝑟𝑖(𝑡) =  𝛽0𝑖 + 𝛽1 + 𝛽2 × 𝑡𝑟𝑡𝑖 + 𝛽3𝑏𝑎𝑑𝑝𝑟𝑜𝑔𝑖          (2) 
where, 
𝛽0𝑖~𝑁(𝛽0, 𝜎0
2).  
Here 𝛽0𝑖  is the random intercept, 𝛽1 is the average rate of change of the biomarker for a patient in the control 
group, and 𝛽1 + 𝛽2 is the average rate of change of the biomarker for a patient in the experimental treatment 
group. trti is a binary covariate that equals 1 when the patient is in the experimental group and 0 otherwise, 
badprogi is a binary covariate that equals 1 when a patient has poor prognosis at baseline and 0 otherwise, and 
𝛽3 is the change in the intercept for a patient with a poor prognosis compared to a patient with a good prognosis. 
We simulated data in which biomarker observations were made at randomisation, and at 21 day intervals after 
randomisation. Biomarker observations were subject to an error term with a standard normal distribution with 
mean 0 and variance 𝜎2. 
10 
 
We used a 2-component mixture Weibull baseline survival function and the general survival simulation 
framework described by Crowther and Lambert (2013)[26] to simulate survival dependent on a time-varying 
biomarker. Simulating using a mixture model allows us to simulate complex hazard functions, which is 
important given the recognition that real-world survival data frequently does not follow standard parametric 
distributions.[27] The model can be written as:  
𝑆0(𝑡) =  𝑝 exp(−𝜆1𝑡
𝛾1) + (1 − 𝑝) exp(−𝜆2𝑡
𝛾2)  (3) 
where  𝜆1, 𝜆2 > 0  and 𝛾1, 𝛾2 > 0 are scale and shape parameters, respectively. The mixture parameter, p, with 
0 ≤ 𝑝 ≤ 1, represents the contribution of the first Weibull to the overall survival model, and  1 − 𝑝 represents 
the contribution of the second Weibull. The related baseline hazard function is: 
ℎ0(𝑡) =  
𝜆1𝛾1𝑝𝑡
𝛾1−1exp(−𝜆1𝑡
𝛾1)+𝜆2𝛾2(1−𝑝)𝑡
𝛾2−1exp(−𝜆2𝑡
𝛾2)
𝑝 exp(−𝜆1𝑡
𝛾1)+(1−𝑝) exp(−𝜆2𝑡
𝛾2)
         (4) 
The linear predictor of the survival model was incorporated as follows: 
ℎ𝑖(𝑡) = ℎ0(𝑡) exp[𝛿1 𝑡𝑟𝑡𝑖 + 𝜂 t × 𝑡𝑟𝑡𝑖 + 𝛿2 𝑏𝑎𝑑𝑝𝑟𝑜𝑔𝑖 + 𝛼 𝑏𝑖𝑜𝑚𝑎𝑟𝑘𝑒𝑟𝑖(𝑡)]    (5) 
where 𝛿1 is the direct effect of treatment at time 0, η is the rate at which the direct effect of treatment changes 
with time, 𝛿2 is the impact of poor prognosis, and α is the coefficient of the underlying biomarker level.  
Disease progression times were simulated to equal survival times multiplied by a value from a beta distribution 
with shape parameters (5,10). We assumed that patients had consultations with their clinician every 21 days, and 
that disease progression was observed to have occurred at the first consultation following the actual progression 
event.  
We simulated random entry into the study. The maximum administrative censoring time was set at 548 days (1.5 
years), and patients in the control group had a random uniform entry time from 0 to 183 days – hence their 
administrative censoring times ranged from 365 to 548 days.  
In the ‘base case’ (Scenario 1) simulation, the parameter values for the mixture Weibull survival model and the 
longitudinal biomarker model were: 
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𝛽0 = 20 , 𝜎0
2 = 1 , β1 = 0.04 , 𝛽2 = −0.02 , 𝛽3 = 2.5, 𝜎
2 = 1,  𝛿1 = −1.30, 𝛿2 = 0.3, 𝛼 = 0.01, 𝜆1 =
0.00001, 𝛾1 = 2.0,  𝜆2 = 0.00001, 𝛾2 = 0.8 , 𝑝 = 0.5, 𝜂 = 0.003.   
An example of the Kaplan-Meier curves and hazard function produced by the simulation model (in the absence 
of treatment switching) from a single simulated data set using the base case parameter values is presented in 
Figure 2. We simulated a hazard function that was initially low, then steadily increased before decreasing 
towards the end of the trial follow-up. This is similar to the data simulated in our previous study,[19] and we 
believe that this is typical of the types of hazards observed in a metastatic oncology RCT setting: initial hazards 
are likely to be low, because trial inclusion criteria dictate that trial participants usually have relatively good 
prognosis. The seriousness of the disease dictates that hazards are likely to rise, before falling in the longer term 
as those who remain alive are of relatively better prognosis. The resulting Kaplan Meier curves are also 
reminiscent of those observed in the trametinib in metastatic melanoma example presented in Figure 1. 
Treatment effect in the experimental group 
For the majority of scenarios investigated we cannot summarise the treatment effect experienced in the 
experimental group using a single value, because our hazard function includes ‘t’ terms. The treatment effect 
initially increases during the period of greatest hazard, before falling in the longer-term. We believe that this is 
representative of a realistic treatment effect, which falls in the longer-term when the initial treatment effect may 
have worn off, or when only better prognosis patients remain alive.  
In one set of scenarios we excluded the ‘t’ terms from the data generating mechanism and did not use a mixture 
survival model, in order to test the different methods in instances with a constant treatment effect (i.e. with 
proportional hazards) over time. In these scenarios re-censoring should not produce bias and comparing results 
from scenarios with a time-dependent treatment effect to scenarios with a constant treatment effect should show 
how sensitive methods that apply re-censoring are to a time-dependent treatment effect. In this set of scenarios 
the true treatment effect was known, with 𝛿1 representing the log hazard ratio. In scenarios that incorporated a 
time-dependent treatment effect, to give an idea of the size of the treatment effect we calculated the ‘average’ 
HR and AF by generating scenario-specific survival data for a large number of patients (1 000 000) without 
applying switching, and by fitting Cox and accelerated failure time models to this.     
The switching mechanism 
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Only patients in the control group could switch treatments, and switching could only occur during the three 
consultations immediately following disease progression – switching was not permitted before disease 
progression, to reflect the treatment switching typically seen in metastatic cancer trials.[1] During this ‘at risk’ 
period, the probability of switching declined for each individual patient with each simulated consultation, which 
were assumed to occur every 21 days. The probability of switching during the ‘at risk’ period was calculated 
using a logistic function and depended upon the time of observed disease progression, and the observed 
biomarker value at that time-point. In reality, switching is highly likely to be related to prognosis and therefore 
in half of our simulated scenarios patients with relatively good prognosis were more likely to switch, and in the 
other half switching was more likely in patients with relatively poor prognosis. Switching probabilities were 
varied to test different switching proportions. Further details on the probability of switching in different 
simulated groups are presented in Appendix A.   
Treatment effect in switchers 
For patients who were simulated to switch from the control treatment onto the experimental treatment, the 
period after switching was multiplied by a factor (ω) to estimate survival times incorporating the impact of 
switching (𝑇𝑧𝑖), using the following approach:    
𝑇𝑧𝑖 = 𝑇𝐴𝑖 + 𝜔 × 𝑇𝐵𝑖      (6) 
where 𝑇𝐴𝑖  represents the time of switching and 𝑇𝐵𝑖  represents the survival time after the switch point that was 
simulated to occur in the absence of switching. This is the same as the accelerated failure time model presented 
in (1), but here we denote the treatment effect as 𝜔 rather than 𝑒−𝜓0.   
The magnitude of ω was varied across scenarios to represent relative reductions in the average treatment effect 
(in terms of an AF) of 0% and 20%. This allowed us to test scenarios in which the ‘common treatment effect’ 
assumption did and did not hold. For instance, in scenarios where the common treatment effect assumption held, 
the scenario-specific survival data were generated for 1 000 000 patients without applying switching and the 
RPSFTM was applied to estimate 𝜓0, with ω then set to equal 𝑒
−𝜓0 . In scenarios where a 20% treatment effect 
reduction was simulated ω was set to equal ((𝑒−𝜓0 − 1) × 0.8) + 1. In scenarios where there was a time-
dependent treatment effect, the common treatment effect assumption did not hold in the truest sense even when 
the treatment effect received by switchers was the same as the average treatment effect in the experimental 
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group, because the treatment effect in the experimental group was time-dependent. However, in the set of 
scenarios that did not incorporate a time-dependent treatment effect the common treatment effect assumption 
did truly hold.  
Scenarios investigated 
The simulated data generating mechanism had several variables for which values had to be assumed. These are 
listed in Appendix B, together with details on how they were altered in the ‘base’ scenarios. Scenarios were 
devised in order to cover key variables that were likely to change in trials in the real world, and also to test the 
sensitivities of the different adjustment methods with respect to their key assumptions. Scenarios were run 
varying the following characteristics: 
 Severity of disease: moderate severity (restricted mean survival in control group approximately 357 days, 
administrative censoring proportion approximately 40-50%); severe (restricted mean survival in control group 
approximately 228 days, administrative censoring proportion approximately 17-25%) 
 Relative treatment effect reduction received by switchers: 20%; 0% 
 Switch proportion: moderate (approximately 55% of control group patients who experienced disease 
progression) ; low (approximately 25% of control group patients who experienced disease progression)  
 Treatment effect: high (average HR under the incorrect assumption of proportional hazards, approximately 
0.56); moderate (average HR approximately 0.80)  
 Switcher prognosis: good prognosis more likely to switch; poor prognosis more likely to switch;  
 Time dependency of treatment effect: moderate (α = 0.01, η = 0.003); zero (α = 0.00, η = 0.000); strong 
(α = 0.01, η = 0.006) 
Using a 2x2x2x2x2x3 factorial design resulted in a total of 96 scenarios. The scenarios were numbered 1-96 
with all levels of one factor nested inside one level of the next factor, following the order listed above. The first 
16 scenarios were regarded as the ‘base’ scenarios, varying the first four factors, and holding switcher prognosis 
as “good prognosis more likely to switch” and the time dependency of the treatment effect as “moderate”. One 
thousand simulations were run for each scenario. Scenario settings are detailed in Appendix C.  
Adjustment methods compared 
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To provide context on the performance of the adjustment methods, we present results from a ‘No Switching’ 
analysis, representing the results of a standard ITT analysis undertaken on the simulated dataset before 
switching was applied. This does not represent a feasible estimator, but provides a useful upper bound for 
adjustment method performance which may be considered a ‘gold standard’. We also present a standard ITT 
analysis after switching has been applied. 
For the RPSFTM we used a log-rank test within the g-estimation procedure using the Stata command strbee.[28] 
We included the RPSFTM with and without re-censoring (referred to as RPSFTM and RPSFTMnr 
respectively).  
We applied the two-stage method using a Weibull model, used disease progression as the secondary baseline 
time-point, and included covariates for switching, baseline prognosis group, observed biomarker value at time 0, 
observed time-to-disease progression, and observed biomarker value at disease progression. We included the 
two-stage method with and without re-censoring (referred to as TSE and TSEnr respectively).  
Performance measures 
We used control group restricted mean survival time (RMST) as our true value, or estimand, upon which to base 
our performance measures. We did not focus on estimated treatment effects because in the majority of scenarios 
we did not simulate proportional hazards. Our simulated survival function was not analytically tractable so for 
each scenario we simulated data for 1 000 000 patients without incorporating treatment switching, and we 
estimated the RMST at 548 days (the maximum administrative censoring time in the simulated datasets). 
Because this value is the product of a simulation rather than a calculation it is prone to error, but this is likely to 
be extremely minimal given the large number of patients simulated.  
To estimate RMST at 548 days for each of the adjustment methods, we could not simply calculate the area 
under the counterfactual Kaplan-Meier curve because this may restrict the mean estimation to too short a time 
period, particularly for methods that apply re-censoring. Instead, we used what we believe is the most 
appropriate approach given the context that these methods are usually used in – that is, for health technology 
assessment. TSE, TSEnr, RPSFTM and RPSFTMnr each provide counterfactual datasets, to which we fitted 
flexible parametric models in order to obtain the survivor function extrapolated to 548 days. The Stata command 
stpm2 was used to fit the models on the log cumulative hazard scale, with 3 knots placed at equally spaced 
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centiles of the distribution of the log survival times [29] Where the final observed survival time was less than 
548 days, the RMST at 548 days was estimated through a linear extrapolation from the last knot. This is in line 
with recommendations made in the UK for undertaking survival modelling in the absence of proportional 
hazards.[30,31] To estimate confidence intervals (CIs), counterfactual datasets were derived for the lower and 
upper 95% CIs of the estimated treatment effect (𝜓) for each of the adjustment methods. Then flexible 
parametric models were fitted as described above to estimate 95% CIs for RMST at 548 days.  
We evaluated the performance of methods according to the percentage bias in their estimate of control group 
RMST at 548 days. Percentage bias was estimated by taking the difference between the mean estimated RMST 
and the true RMST and expressing this as a percentage of true RMST.[32] The root mean squared error (RMSE) 
of the percentage bias was calculated to provide information on the variability of estimates in combination with 
percentage bias. The empirical standard error (SE) of the RMST estimate was also calculated for each method, 
as was coverage, defined as the proportion of simulations where the 95% confidence interval of the RMST 
contained the true RMST. Convergence was measured, defined as the proportion of times that each method 
resulted in an estimate of control group RMST. Percentage bias, RMSE, empirical SE and coverage were 
calculated based upon simulations in which convergence occurred. Monte Carlo standard errors were also 
calculated for each performance measure, for each method.   
RESULTS 
We present detailed results from 8 of the base scenarios that illustrate the key findings. First we report key 
results in scenarios that involved moderate (approximately 55%) and low (approximately 25%) switching 
proportions, before summarising the extent to which these reflect the results of the other scenarios simulated.  
A summary table describing the characteristics of each scenario is presented in Appendix D. Appendices E, F 
and G present the percentage bias, empirical standard error and RMSE respectively across all scenarios for each 
method.  
Scenarios with moderate switching proportions 
Tables 1 and 2 present detailed results from Scenarios 1, 2, 3 and 4, in which the switching proportion was 
approximately 57 – 58% of at-risk patients (40 – 55% of all control group patients).   
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The characteristics of Scenario 1, with regard to survival times, switch proportion, treatment effect and 
censoring proportion, are described in Table 1. To summarise, this scenario incorporated a moderate switch 
proportion, a large treatment effect, a high censoring proportion, and violated the common treatment effect 
assumption. The average HR and AF are included in Tables 1, 2, 3 and 4 for illustrative purposes, to give an 
idea of the size of the treatment effect. Given that neither the proportional hazards nor constant acceleration 
factor assumptions held in our simulations, these estimates are prone to error.  
As expected, in Scenario 1 the ITT analysis estimated a higher control group RMST than would have been 
observed in the absence of treatment switching, equivalent to a percentage bias of 6.5%. The RPSFTM and TSE 
analyses that applied re-censoring both under-estimated control group RMST, with the level of bias more 
appreciable for the RPSFTM (percentage bias -5.3%, compared to -1.9% for TSE). In contrast, RPSFTMnr and 
TSEnr analyses over-estimated control group RMST (percentage bias 2.1% for the RPSFTMnr and 3.0% for the 
TSEnr).  
The only substantive difference between Scenario 1 and Scenario 2 was that disease severity was greater in 
Scenario 2, leading to the censoring proportion being approximately halved. The TSE, TSEnr and RPSFTMnr 
methods were relatively unaffected by this change (percentage bias -1.5%, 3.5% and 1.5% respectively), but the 
percentage bias associated with the RPSFTM increased (percentage bias -8.3%).  
Table 2 presents detailed results of Scenario 3 and Scenario 4. Scenario 3 was approximately equivalent to 
Scenario 1 and Scenario 4 was approximately equivalent to Scenario 2, except the common treatment effect 
assumption held. This had little impact on the TSE and TSEnr analyses. However, in comparison to Scenarios 1 
and 2, in Scenarios 3 and 4 the percentage bias associated with the RPSFTM reduced (percentage bias -2.8% 
and -5.5% in Scenarios 3 and 4 respectively), and the percentage bias associated with the RPSFTMnr increased 
(percentage bias 3.5% and 4.2% respectively).  
Tables 1 and 2 show that coverage was poor for all the adjustment methods, although methods that applied re-
censoring provided better coverage than those that did not. RMSE results demonstrate that the levels of 
variability associated with the different adjustment methods differed importantly. Higher levels of bias were not 
always associated with higher RMSEs. For instance, in all four scenarios TSEnr produced least RMSE aside 
from the gold standard ‘no switching’ analysis, and both the TSEnr and RPSFTMnr produced appreciably lower 
RMSE than TSE and RPSFTM, even when the applications that applied re-censoring resulted in lower 
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percentage bias. This reflects the fact that the empirical standard errors of the percentage bias differed 
substantially between methods. Two-stage and RPSFTM methods that applied re-censoring produced empirical 
standard errors that were close to double the size of those associated with methods that did not apply re-
censoring. Amongst the adjustment methods, the empirical standard error was consistently lowest for the TSEnr. 
This was always higher than for the gold standard ‘no switching’ analysis, but the difference was not substantial. 
Successful estimation was achieved with all of the adjustment methods across Scenarios 1, 2, 3 and 4.  
Scenarios with low switching proportions  
Tables 3 and 4 present detailed results from Scenarios 5, 6, 7 and 8, in which the switching proportion was 
approximately 25% of at-risk patients (17 – 24% of all control group patients). Scenarios 5, 6, 7 and 8 were 
similar to Scenarios 1, 2, 3 and 4, with the only substantive difference the switching proportion.  
The reduced switching proportion had an important impact on the adjustment methods that did not apply re-
censoring, with percentage bias reducing substantially for TSEnr and RPSFTMnr. In Scenarios 5-8 the 
RPSFTMnr and TSEnr always led to lower percentage bias than RPSFTM and TSE, whereas in Scenarios 1-4 
TSE always produced lower percentage bias than TSEnr, and RPSFTM produced lower percentage bias than 
RPSFTMnr in Scenario 3. The direction of the bias remained the same – applications that included re-censoring 
resulted in negative bias, and those that did not apply re-censoring resulted in positive bias. In these scenarios, 
RMSE and empirical standard errors remained substantially lower for TSEnr and RPSFTMnr compared with 
TSE and RPSFTM. TSEnr consistently produced the lowest empirical standard errors and RMSE of the 
adjustment methods, and these were only marginally higher than those produced by the gold standard ‘no 
switching’ analysis. 
Other base case scenarios  
The results presented above provide a good overview of our key findings. RPSFTMnr and TSEnr produced 
positive bias in all 16 base case scenarios, over-estimating control group mean survival. RPSFTM always 
produced negative bias (under-estimating control group mean survival) whereas TSE produced negative bias 
when the treatment effect was high, but occasionally produced positive bias when the treatment effect was low. 
Percentage bias was increased for both methods that applied re-censoring when the treatment effect was high. 
TSE, TSEnr and RPSFTMnr generally produced similar levels of bias – though TSE usually produced bias in 
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the opposite direction. The TSE produced least percentage bias most often (see Table 5) but TSEnr produced the 
lowest RMSE across all scenarios. TSE always produced lower RMSE than RPSFTM, TSEnr always produced 
lower RMSE than RPSFTMnr, and methods that did not apply re-censoring always produced lower RMSE than 
those that did apply re-censoring. The RPSFTM generally performed relatively poorly, only rarely producing 
lower percentage bias than the RPSFTMnr.  
Results according to prognosis of switchers  
Scenarios 17-32 repeated Scenarios 1-16, but patients with a relatively poor prognosis were more likely to 
switch, rather than patients with a relatively good prognosis. The performance of RPSFTM and TSE methods 
was very similar to that observed in Scenarios 1-16. The impact on TSEnr and RPSFTMnr was larger – both 
produced reduced bias and whilst TSEnr continued to consistently produce positive bias, RPSFTMnr produced 
low negative bias in 4 of the 16 scenarios (although the estimated RMST always remained higher than that 
estimated by the RPSFTM). This occurred in scenarios in which the switching proportion was low and the 
common treatment effect assumption was violated.  
Across Scenarios 17-32, RPSFTMnr produced least percentage bias in the most (10) scenarios, followed by TSE 
(5 scenarios, see Table 5). Again, often several methods resulted in similarly low levels of bias. TSEnr produced 
the lowest RMSE in all scenarios, and this was often only marginally higher than the RMSE associated with the 
gold standard ‘no switching’ analysis.  
Scenarios with zero and strong time-dependent treatment effects 
Scenarios 1-32 were repeated in Scenarios 33-64 with the treatment-related HR constant over time, and in 
Scenarios 65-96 with the treatment effect reducing more substantially over time.  
In most of Scenarios 33-64 TSE, RPSFTM, TSEnr and RPSFTMnr produced percentage bias that was 
approximately half the size of that produced in Scenarios 1-32. For the RPSFTM and TSEnr, patterns in results 
were similar to those observed in Scenarios 1-32 – the RPSFTM produced negative bias in all but one scenario 
and TSEnr produced positive bias in all but 5 scenarios. In contrast, the TSE produced bias in varying directions 
in Scenarios 33-64, whereas it consistently produced negative bias in Scenarios 1-32. In particular, TSE 
produced positive bias when good prognosis patients were more likely to switch in Scenarios 33-64. The pattern 
in the direction of bias also altered for the RPSFTMnr in Scenarios 33-64 – positive bias was less consistently 
19 
 
produced when the common treatment effect assumption held, and negative bias was often produced when the 
common treatment effect assumption was violated. All methods generally produced very low levels of bias 
across Scenarios 33-64, with the only exception being the RPSFTM when there was a high, non-common 
treatment effect and a high switching proportion.  
No single method consistently produced least bias in Scenarios 33-64 and often several methods produced 
similarly low levels of percentage bias (Table 5). The range of RMSE produced by the different adjustment 
methods was much narrower in these scenarios, but TSEnr continued to consistently produce the lowest values 
with these again often only marginally higher than those produced by the ‘no switching’ analysis.  
The stronger time-dependency of the treatment effect in Scenarios 65-96 led to marginal increases in the 
percentage bias and RMSE associated with the adjustment methods, and patterns and directions of bias closely 
mimicked those observed in Scenarios 1-32. Again, no single method consistently produced least bias (Table 5). 
TSE, TSEnr and RPSFTMnr were the most consistent, being least affected by scenario characteristics, and 
TSEnr continued to consistently produce the lowest RMSE values.  
DISCUSSION  
Our study demonstrates the value in conducting adjustment analyses with and without re-censoring. Re-
censored and non-re-censored analyses are likely to often produce bias in opposing directions, potentially 
providing additional information on where the true treatment effect is likely to lie.  
In many of the scenarios tested – particularly those with a low and common treatment effect, and a low 
censoring proportion – all adjustment methods produced low percentage bias. TSE, TSEnr and RPSFTMnr 
produced low levels of bias across all scenarios, never performing appreciably worse than other adjustment 
methods. There was a trend towards non-re-censored analyses performing relatively better than re-censored 
analyses when the switching proportion was low and when the treatment effect was high. This is likely to be 
because small switching proportions mean fewer patients become informatively censored, and because re-
censoring leads to a greater loss of information when the treatment effect is high. Perhaps most importantly, the 
direction of bias differed consistently between re-censored and non-re-censored analyses, and therefore the 
choice of method remains important.  
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Our intention was primarily to compare re-censored and non-re-censored analyses within the RPSFTM and TSE 
classes. However, our results also provide new information allowing us to update the comparison between these 
two classes. Whilst no single method produced least percentage bias consistently across all scenarios, TSEnr 
produced the lowest RMSE in all 96 scenarios, suggesting that when bias and variability are considered 
together, it consistently represented the optimal method. However, it remains important to carefully consider 
trial and switching characteristics to assess the likely performance of the different methods. In addition, the 
RPSFTM (with re-censoring) performed substantially worse than other adjustment methods in a subset of 
scenarios, allowing scenarios to be identified in which this method should not be relied upon. 
The RPSFTM with re-censoring consistently produced negative bias (over-estimating the treatment effect) and 
performed substantially worse than other adjustment methods in scenarios with a high, time-dependent 
treatment effect (irrespective of whether there was a common treatment effect) and also when there was not a 
common treatment effect (irrespective of the size of the treatment effect). When the treatment effect decreases 
over time, re-censoring causes a negative bias (more substantially so when the treatment effect is high). In 
addition, when switchers receive a decreased treatment effect the RPSFTM – which assumes that the treatment 
effect is the same in all patients who receive it – will over-adjust survival times for switchers, again causing 
negative bias. Hence, the RPSFTM with re-censoring is clearly prone to negative bias in scenarios such as those 
investigated in this study – two-thirds of scenarios incorporated a treatment effect that reduced over time, and 
half incorporated a violation of the common treatment effect assumption, where switchers received a reduced 
treatment effect. There were only 16 scenarios with a constant, common treatment effect – and one of these 
scenarios represented the only instance in which the RPSFTM produced positive bias. If, in reality, the treatment 
effect is expected to decline over time, or the treatment effect in switchers is expected to be lower than that 
received by patients in the experimental group, an RPSFTM with re-censoring is highly likely to over-estimate 
the treatment effect. If both of these characteristics are expected, an over-estimated treatment effect is even 
more likely. 
The TSE with re-censoring is prone to the same negative bias as the RPSFTM when the treatment effect falls 
over time, but not the negative bias associated with violations of the common treatment effect assumption. This 
explains why the TSE consistently produced more conservative estimates of restricted mean survival than the 
RPSFTM. When there is not a time-dependent treatment effect, the TSE with re-censoring should not result in 
systematic negative bias, and indeed it produced a mixture of positive and negative bias in scenarios that met 
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this criteria. The TSE produced low levels of positive bias in some scenarios with a decreasing treatment effect 
over time, when the treatment effect was low and disease severity was high. This is likely to be because re-
censoring has a smaller impact in these scenarios. The TSE appears to represent a better method than the 
RPSFTM for adjusting for treatment switching unless the treatment effect is common and constant, provided the 
switching mechanism matches the requirements of the TSE method.  
When re-censoring is not applied within RPSFTM and TSE adjustment methods, they are no longer exposed to 
the negative bias associated with a loss of longer-term information in the presence of a treatment effect that 
decreases over time. However, they become exposed to bias associated with informative censoring. The 
RPSFTMnr remains exposed to the negative bias associated with a non-common treatment effect. Originally we 
hypothesised that informative censoring would be associated with positive bias (over-estimates of control group 
survival) when poor prognosis patients were more likely to switch treatments – because more poor prognosis 
patients would be censored at earlier time-points than good prognosis patients. Conversely, when good 
prognosis patients were more likely to switch we expected that not re-censoring would lead to negative bias 
(under-estimates of control group survival), because good prognosis patients would generally be censored at 
earlier time-points. In fact, in scenarios where there was a time-dependent treatment effect, RPSFTMnr and 
TSEnr almost always produced positive bias, irrespective of the prognosis of switchers.  
After thorough investigation, we conclude that this will occur when there are any non-switching long-term 
survivors (see Appendix H for more details). These patients most influence the impact of informative censoring, 
because re-censoring primarily affects the right-hand-side of the Kaplan-Meier curve. The implication is that 
TSE and TSEnr are likely to result in biases in opposing directions when the treatment effect decreases over 
time. It is difficult to conclude which of these biases will be greater – in our simulations TSE and TSEnr often 
produced similar levels of bias, in opposite directions, although as previously mentioned TSEnr always 
produced lower RMSE and therefore may be preferred when the aim is to estimate long-term treatment effects. 
Opposing directions of bias can also be expected with the RPSFTM and RPSFTMnr, provided there is a 
common treatment effect. This is less clear-cut when there is not a common treatment effect, but more confident 
conclusions may be made about which analysis is likely to produce least bias. In these scenarios the RPSFTMnr 
is subject to opposing forces of bias – violation of the common treatment effect assumption induces negative 
bias, whereas informative censoring is likely to cause positive bias. Conversely, the RPSFTM is prone to the 
dual negative biases associated with re-censoring and a non-common treatment effect. Whilst the RPSFTM is 
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likely to result in appreciable negative bias in these scenarios, the direction of bias associated with the 
RPSFTMnr depends upon the extent to which negative and positive biases cancel out. Given that these biases 
are likely to cancel out to some extent, it seems reasonable to conclude that the RPSFTMnr is likely to produce 
lower bias than the RPSFTM in these scenarios – this was almost exclusively the case in our simulations. The 
RPSFTMnr also consistently produced lower RMSE than RPSFTM and therefore may be preferred when the 
aim is to estimate long-term treatment effects. 
We are aware of three studies that have presented analyses adjusting for treatment switching both with and 
without re-censoring, or which have investigated the impact of re-censoring. White et al. (1999) presented 
RPSFTM analyses undertaken on the Concorde trial of immediate versus deferred zidovudine for patients with 
HIV. The analysis without re-censoring led to more conservative estimates of the treatment effect and the 
authors observed that the treatment effect appeared to decrease over time. They concluded that their re-censored 
analysis may have over-estimated the treatment effect, whilst their non-re-censored analysis may have produced 
an under-estimate because switchers appeared to have a better prognosis than non-switchers.[15] Latimer et al. 
reported an adjustment analysis applied to an RCT comparing trametinib and chemotherapy in patients with 
metastatic melanoma.[7] RSPFTM and two-stage analyses which excluded re-censoring produced the most 
conservative estimates of the treatment effect. The authors found evidence of a decreasing treatment effect over 
time, and concluded that the analyses that excluded re-censoring were likely to be least biased. The pattern in 
these results is identical to that seen in our study. This was not the case in White and Goetghebeur’s analysis of 
an RCT comparing two anti-hypertensive treatments affected by treatment switching. Heavily re-censored 
analyses resulted in less optimistic estimates of the treatment effect, because the treatment effect only became 
apparent in the long-term.[18] It is possible that in some situations the treatment effect may rise and then fall 
over time – in fact this was the pattern simulated in our scenarios (see Figure2). If re-censoring leads to analyses 
being based on data observed before the treatment effect becomes apparent, under-estimates of the long-term 
treatment effect may result. This was not the case in our simulations, but with a more delayed treatment effect it 
is conceivable. 
Previous authors have noted that failing to re-censor may result in a small bias but a large gain in precision.[15] 
We found that failing to re-censor often led to a large gain in precision and reduced bias. RMSE and empirical 
standard errors were substantially reduced when re-censoring was excluded from RPSFTM and TSE analyses, 
highlighting important advantages associated with not re-censoring. 
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Our study has limitations. We sought to investigate many realistic scenarios, but a simulation study can never be 
exhaustive. Our choice of endpoint could also be questioned – we used restricted means to limit the impact of 
extrapolation on our results. When extrapolation is required to estimate unrestricted means (for HTA purposes) 
bias associated with all adjustment methods could increase, but methods that re-censor may be most seriously 
affected owing to the associated loss of information. Extrapolation should always be undertaken with care, 
incorporating external information where possible to provide credible projections.[30,31,33] We could instead 
have chosen to use a mean restricted to a shorter time-period, to prevent the results of re-censored analyses from 
being affected by extrapolation. However, given that our intention is to help inform the choice of adjustment 
method used primarily within HTA analyses we deemed it of little value to assess the performance of the 
different adjustment methods in estimating short-term treatment effects. Also, we recognise that results of 
survival analyses are usually summarised as hazard ratios. The majority of our scenarios had non-proportional 
hazards so HRs were inappropriate for measuring performance. Despite this, we did calculate ‘average’ HRs to 
allow assessment of adjusted HRs. This is presented in Appendix I. We found that estimates of HRs were prone 
to higher levels of bias than estimates of restricted mean survival – particularly if there is a time-dependent 
treatment effect and re-censoring is used. This should be borne in mind if adjustment analyses are summarised 
using HRs. 
Also, as with previous simulation studies on switching adjustment methods, we did not incorporate 
bootstrapping for confidence intervals.[19,20] Coverage levels associated with the adjustment analyses are 
correspondingly poor because confidence intervals only took into account uncertainty in the treatment effect – 
not the uncertainty in the underlying survival distribution. In reality, the entire adjustment process should be 
bootstrapped to obtain appropriate confidence intervals.  
Both re-censored and non-re-censored adjustment analyses are prone to bias, depending upon scenario 
characteristics. Our study provides valuable information on the likely direction and extent of these biases, and 
on their variability. Analyses that exclude re-censoring are likely to produce under-estimates of the treatment 
effect, irrespective of the perceived prognosis of switchers. Re-censored analyses are likely to produce over-
estimates of the treatment effect if the treatment effect decreases over time, especially RPSFTM analyses if 
switchers receive a reduced treatment effect. Our results can be used to enable better interpretation of treatment 
switching adjustment analyses, by helping determine a range in which the true treatment effect is likely to lie. 
We suggest that analyses should be conducted with and without re-censoring, and that analyses that incorporate 
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re-censoring should not always represent the default approach when the objective is to estimate long-term 
survival times and treatment effects. This could be pivotal in the context of HTA, where accurate estimates of 
long-term treatment effects are critical to evaluations of the cost-effectiveness of novel treatments.   
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Table 1:  Scenarios 1 and 2 – performance measures for estimation of control arm RMST 
Scenario details Method 
Bias (% of true 
RMST) 
Empirical SE  (% of 
true RMST)  
RMSE  (% of true 
RMST) Coverage (%) Successful estimation (%) 
Scenario number: 1 
True RMST: 
    Control:  357 
    Experimental:  430 
Mean switch: 57% 
True ave. HR: 0.57 
True ave. AF: 1.53 
Mean censored: 49% 
Switcher treatment effect: 
    20% reduction 
No switching 0.2 3.8 3.8 94.3 100 
ITT 6.5 3.6 7.5 58.8 100 
TSE -1.9 6.6 6.9 66.8 100 
TSEnr 3.0 4.0 5.0 33.6 100 
RPSFTM -5.3 9.3 10.7 56.8 100 
RPSFTMnr 2.1 5.1 5.5 36.0 100 
min/max MC error 0.1/0.3 0.1/0.2 0.1/0.3 0.7/1.6 - 
Scenario number: 2 
True RMST: 
    Control:  228 
    Experimental:  322 
Mean switch: 58% 
True ave. HR: 0.57 
True ave. AF: 1.85 
Mean censored: 26% 
Switcher treatment effect: 
    20% reduction 
No switching 0.2 6.1 6.1 93.4 100 
ITT 12.7 6.0 14.1 45.0 100 
TSE -1.5 8.8 8.9 63.4 100 
TSEnr 3.5 6.8 7.6 36.6 100 
RPSFTM -8.3 12.9 15.3 53.9 100 
RPSFTMnr 1.6 8.6 8.8 41.4 100 
min/max MC error 0.2/0.4 0.1/0.3 0.2/0.3 0.8/1.6 - 
 
Note: RMST: restricted mean survival time; HR: hazard ratio; AF: acceleration factor; SE: standard error; RMSE: root mean squared error; MC: Monte-Carlo; ITT: intention 
to treat; TSE: two-stage estimation; TSEnr: two-stage estimation without re-censoring; RPSFTM: rank preserving structural failure time model; RPSFTMnr: rank preserving 
structural failure time model without re-censoring  
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Table 2:  Scenarios 3 and 4 – performance measures for estimation of control arm RMST 
Scenario details Method Percent bias Empirical SE of % bias  RMSE of % bias  Coverage (%) Successful estimation (%) 
Scenario number: 3 
True RMST: 
    Control:  357 
    Experimental:  430 
Mean switch: 57% 
True ave. HR: 0.57 
True ave. AF: 1.53 
Mean censored: 50% 
Switcher treatment effect: 
    0% reduction 
No switching -0.0 3.7 3.7 94.4 100 
ITT 7.5 3.4 8.3 46.7 100 
TSE -2.3 6.9 7.3 63.1 100 
TSEnr 3.5 3.9 5.3 29.4 100 
RPSFTM -2.8 8.9 9.3 62.1 100 
RPSFTMnr 3.5 4.9 6.1 30.7 100 
min/max MC error 0.1/0.3 0.1/0.2 0.1/0.3 0.7/1.6 - 
Scenario number: 4 
True RMST: 
    Control:  228 
    Experimental:  322 
Mean switch: 57% 
True ave. HR: 0.57 
True ave. AF: 1.85 
Mean censored: 26% 
Switcher treatment effect: 
    0% reduction 
No switching -0.1 5.7 5.7 94.7 100 
ITT 15.1 5.5 16.0 29.1 100 
TSE -3.5 9.1 9.8 64.3 100 
TSEnr 4.0 6.5 7.6 33.0 100 
RPSFTM -5.5 11.8 13.0 64.9 100 
RPSFTMnr 4.2 8.2 9.2 40.5 100 
min/max MC error 0.2/0.4 0.1/0.3 0.1/0.3 0.7/1.6 - 
Note: RMST: restricted mean survival time; HR: hazard ratio; AF: acceleration factor; SE: standard error; RMSE: root mean squared error; MC: Monte-Carlo; ITT: intention 
to treat; TSE: two-stage estimation; TSEnr: two-stage estimation without re-censoring; RPSFTM: rank preserving structural failure time model; RPSFTMnr: rank preserving 
structural failure time model without re-censoring 
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Table 3:  Scenarios 5 and 6 – performance measures for estimation of control arm RMST 
Scenario details Method Percent bias Empirical SE of % bias  RMSE of % bias  Coverage (%) Successful estimation (%) 
Scenario number: 5 
True RMST: 
    Control:  357 
    Experimental:  430 
Mean switch: 25% 
True ave. HR: 0.57 
True ave. AF: 1.53 
Mean censored: 48% 
Switcher treatment effect: 
    20% reduction 
No switching 0.1 3.7 3.7 94.6 100 
ITT 2.8 3.6 4.5 90.0 100 
TSE -1.6 5.7 5.9 53.5 100 
TSEnr 1.4 3.7 4.0 24.7 100 
RPSFTM -3.8 7.2 8.2 36.3 100 
RPSFTMnr 0.9 4.1 4.2 17.2 100 
min/max MC error 0.1/0.2 0.1/0.2 0.1/0.2 0.7/1.6 - 
Scenario number: 6 
True RMST: 
    Control:  228 
    Experimental:  322 
Mean switch: 25% 
True ave. HR: 0.57 
True ave. AF: 1.85 
Mean censored: 25% 
Switcher treatment effect: 
    20% reduction 
No switching 0.3 6.1 6.1 93.4 100 
ITT 5.5 5.9 8.0 87.2 100 
TSE -2.0 8.0 8.2 57.2 100 
TSEnr 1.7 6.2 6.4 26.9 100 
RPSFTM -6.5 10.4 12.3 40.3 100 
RPSFTMnr 0.8 6.9 6.9 21.8 100 
min/max MC error 0.2/0.3 0.1/0.2 0.1/0.3 0.8/1.6 - 
Note: RMST: restricted mean survival time; HR: hazard ratio; AF: acceleration factor; SE: standard error; RMSE: root mean squared error; MC: Monte-Carlo; ITT: intention 
to treat; TSE: two-stage estimation; TSEnr: two-stage estimation without re-censoring; RPSFTM: rank preserving structural failure time model; RPSFTMnr: rank preserving 
structural failure time model without re-censoring 
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Table 4:  Scenarios 7 and 8 – performance measures for estimation of control arm RMST 
Scenario details Method Percent bias Empirical SE of % bias  RMSE of % bias  Coverage (%) Successful estimation (%) 
Scenario number: 7 
True RMST: 
    Control:  357 
    Experimental:  430 
Mean switch: 57% 
True ave. HR: 0.57 
True ave. AF: 1.53 
Mean censored: 25% 
Switcher treatment effect: 
    0% reduction 
No switching -0.2 3.8 3.8 94.5 100 
ITT 3.0 3.7 4.8 87.4 100 
TSE -2.3 6.7 7.1 48.6 100 
TSEnr 1.3 3.9 4.1 25.1 100 
RPSFTM -3.0 7.3 7.9 35.5 100 
RPSFTMnr 1.2 4.2 4.3 16.5 100 
min/max MC error 0.1/0.2 0.1/0.2 0.1/0.2 0.7/1.6 - 
Scenario number: 8 
True RMST: 
    Control:  228 
    Experimental:  322 
Mean switch: 25% 
True ave. HR: 0.57 
True ave. AF: 1.85 
Mean censored: 25% 
Switcher treatment effect: 
    0% reduction 
No switching 0.1 5.7 5.7 95.4 100 
ITT 6.2 5.6 8.3 86.4 100 
TSE -3.3 8.4 9.0 59.9 100 
TSEnr 1.8 5.9 6.1 28.7 100 
RPSFTM -5.5   10.0 11.4 44.9 100 
RPSFTMnr 1.5 6.6 6.7 21.9 100 
min/max MC error 0.2/0.3 0.1/0.2 0.1/0.2 0.7/1.6 - 
Note: RMST: restricted mean survival time; HR: hazard ratio; AF: acceleration factor; SE: standard error; RMSE: root mean squared error; MC: Monte-Carlo; ITT: intention 
to treat; TSE: two-stage estimation; TSEnr: two-stage estimation without re-censoring; RPSFTM: rank preserving structural failure time model; RPSFTMnr: rank preserving 
structural failure time model without re-censoring 
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Table 5: Methods producing least bias 
Method Scenarios 
1-16 
Scenarios 
17-32 
Scenarios 
33-48 
Scenarios 
49-64 
Scenarios 
64-80 
Scenarios 
81-96 
Total 
ITT 0 0 0 0 0 0 0 
TSE 10 5 6 4 8 3 36 
TSEnr 0 1 1 4 3 4 13 
RPSFTM 1 0 4 3 3 1 12 
RPSFTMnr 5 10 5 5 2 8 35 
Note: ITT: intention to treat; TSE: two-stage estimation; TSEnr: two-stage estimation without re-
censoring; RPSFTM: rank preserving structural failure time model; RPSFTMnr: rank preserving 
structural failure time model without re-censoring 
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Figure 1. (a) Overall survival in primary efficacy population. (A). Rank-preserving structural failure time models (RPSFTM) with re-censoring. (B). RPSFTM without re-
censoring. (C). Two-stage method with re-censoring. (D). Two-stage method without re-censoring. Reproduced from Latimer et al, 2016 [7]  
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Figure 2. One simulated dataset from Scenario 1 with no switching: (a) Overall survival Kaplan–Meier (b) Smoothed hazard rate  
(a)                                                                                               (b) 
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